olivLaw · US equity research
Koninklijke Philips N.V. PHG
X-Ray Apparatus & Tubes & Related Irradiation Apparatus · SIC 3844 · Vertical: Instruments, medical and optical goods (SIC 384x)
Philips is a global medical technology group that designs imaging and therapy systems, monitoring solutions and personal health products. The company focuses its strategy on AI-enabled innovation, on rebuilding trust after the Respironics product safety issues, and on profitable growth for 2026-2028. For X-ray apparatus, the relevant segment is Diagnosis & Treatment, where imaging and image guided therapy form a major part of sales.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 06 Nov 2026, Koninklijke Philips N.V. (PHG) stock was 30.35 USD (−0.52% on the day), with beta 0.84, 52-week range 23.81–32.91 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 76.4
- overbought (≥ 70)
- Bollinger (20, 2)
- 23.38 – 30.56
- in the upper half of the band · %B 0.97 · band width 26.6%
- SMA 50 / 200
- 25.80 / 27.24
- mixed trend
- MACD (12, 26, 9)
- 1.24 / 0.78
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +26.0% | −5.9% | +31.9 pp | — |
| 3 months | +13.5% | −4.6% | +18.2 pp | — |
| 6 months | +11.5% | +0.2% | +11.3 pp | — |
| Year to date | +12.1% | +7.4% | +4.7 pp | — |
| 1 year | +7.5% | +8.2% | −0.7 pp | −22.0% |
| 3 years | +51.3% | +68.4% | −17.1 pp | −18.3% |
| 5 years | −36.4% | +56.5% | −92.9 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
the price (USD) and the reports are in different currencies
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18.1 bn | 17.1 bn | 17.3 bn | 17.2 bn | 17.8 bn | 18.2 bn | 18.0 bn | 17.8 bn |
| Revenue YoY | +1.9% | −5.4% | +1.0% | −0.9% | +3.9% | +1.9% | −0.8% | −1.0% |
| Net income | 1.1 bn | 1.2 bn | 1.2 bn | 3.3 bn | -1.6 bn | -466.0 m | -702.0 m | 895.0 m |
| Net income YoY | −34.2% | +7.1% | +1.7% | +179.6% | −148.4% | unavailable | unavailable | unavailable |
| Diluted EPS | 1.14 | 1.25 | 1.29 | 3.50 | -1.69 | -0.49 | -0.75 | 0.93 |
| Diluted EPS YoY | −34.9% | +9.6% | +3.2% | +171.3% | −148.3% | unavailable | unavailable | unavailable |
| net % | 6.0% | 6.8% | 6.9% | 19.3% | -9.0% | -2.6% | -3.9% | 5.0% |
| Free cash flow | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 2.8 bn EUR
- Financial debt
- 7.0 bn EUR
- Net debt
- 4.2 bn EUR
- Equity
- 11.0 bn EUR
- Total assets
- 26.9 bn EUR
- Debt / equity
- 0.64x
- Current ratio
- 1.32x
- ROE
- 7.8%
- ROA
- 3.2%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (EUR)
Margins
Income statement · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 17.3 bn | 17.2 bn | 17.8 bn | 18.2 bn | 18.0 bn | 17.8 bn | SEC (XBRL)· 19 Feb 2026verified |
| Cost of revenue | 9.5 bn | 10.0 bn | 10.6 bn | 10.7 bn | 10.2 bn | 9.8 bn | SEC (XBRL)· 19 Feb 2026verified |
| Gross profit | 7.8 bn | 7.2 bn | 7.2 bn | 7.4 bn | 7.8 bn | 8.1 bn | SEC (XBRL)· 19 Feb 2026verified |
| Research & development | 1.8 bn | 1.8 bn | 2.1 bn | 1.9 bn | 1.7 bn | 1.7 bn | SEC (XBRL)· 19 Feb 2026verified |
| Operating income | 1.3 bn | 553.0 m | -1.5 bn | -115.0 m | 529.0 m | 1.4 bn | SEC (XBRL)· 19 Feb 2026verified |
| Depreciation & amortisation | 1.5 bn | 1.3 bn | 1.6 bn | 1.3 bn | 1.4 bn | 1.1 bn | SEC (XBRL)· 19 Feb 2026verified |
| EBITDA | 2.7 bn ≈ | 1.9 bn ≈ | 73.0 m ≈ | 1.1 bn ≈ | 1.9 bn ≈ | 2.5 bn ≈ | SEC (XBRL)· 19 Feb 2026derived |
| Interest expense | 202.0 m | 188.0 m | 258.0 m | 376.0 m | 387.0 m | 346.0 m | SEC (XBRL)· 19 Feb 2026verified |
| Pre-tax income | 1.2 bn | 509.0 m | -1.7 bn | -526.0 m | 123.0 m | 1.2 bn | SEC (XBRL)· 19 Feb 2026verified |
| Income tax | 212.0 m | -103.0 m | -113.0 m | -73.0 m | 963.0 m | 282.0 m | SEC (XBRL)· 19 Feb 2026verified |
| Net income | 1.2 bn | 3.3 bn | -1.6 bn | -466.0 m | -702.0 m | 895.0 m | SEC (XBRL)· 19 Feb 2026verified |
| Diluted EPS | 1.29 | 3.50 | -1.69 | -0.49 | -0.75 | 0.93 | SEC (XBRL)· 19 Feb 2026verified |
| Weighted average diluted shares | — | — | 951.8 m | 948.3 m | 933.4 m | 962.5 m | SEC (XBRL)· 19 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 3.2 bn | 2.3 bn | 1.2 bn | 1.9 bn | 2.4 bn | 2.8 bn | SEC (XBRL)· 19 Feb 2026verified |
| Receivables | 4.2 bn | 3.8 bn | 4.1 bn | 3.7 bn | 3.7 bn | 3.5 bn | SEC (XBRL)· 19 Feb 2026verified |
| Inventories | 3.0 bn | 3.5 bn | 4.0 bn | 3.5 bn | 3.2 bn | 2.9 bn | SEC (XBRL)· 19 Feb 2026verified |
| Current assets | 11.2 bn | 10.3 bn | 10.3 bn | 9.9 bn | 10.0 bn | 9.9 bn | SEC (XBRL)· 19 Feb 2026verified |
| Property, plant & equipment, net | 2.7 bn | 2.7 bn | 2.6 bn | 2.5 bn | — | — | SEC (XBRL)· 20 Feb 2024verified |
| Goodwill | 8.0 bn | 10.6 bn | 10.2 bn | 9.9 bn | 10.4 bn | 9.3 bn | SEC (XBRL)· 19 Feb 2026verified |
| Intangibles (excl. goodwill) | 3.0 bn | 3.7 bn | 3.5 bn | 3.2 bn | 3.0 bn | 2.6 bn | SEC (XBRL)· 19 Feb 2026verified |
| Total assets | 27.7 bn | 31.0 bn | 30.7 bn | 29.4 bn | 29.0 bn | 26.9 bn | SEC (XBRL)· 19 Feb 2026verified |
| Accounts payable | 2.1 bn | 1.9 bn | 2.0 bn | 1.9 bn | 1.8 bn | 1.9 bn | SEC (XBRL)· 19 Feb 2026verified |
| Short-term debt | 1.2 bn | 459.0 m | 842.0 m | 122.0 m | 92.0 m | 52.0 m | SEC (XBRL)· 19 Feb 2026verified |
| Long-term debt | 5.7 bn | 6.5 bn | 7.3 bn | 7.0 bn | 7.1 bn | 6.9 bn | SEC (XBRL)· 19 Feb 2026verified |
| Current liabilities | 7.7 bn | 7.5 bn | 7.9 bn | 8.3 bn | 8.1 bn | 7.5 bn | SEC (XBRL)· 19 Feb 2026verified |
| Total liabilities | — | — | — | 17.3 bn | 16.9 bn | 16.0 bn | SEC (XBRL)· 19 Feb 2026verified |
| Equity | 11.9 bn | 14.5 bn | 13.3 bn | 12.1 bn | 12.0 bn | 11.0 bn | SEC (XBRL)· 19 Feb 2026verified |
| Shares outstanding at year end | 905.1 m | 870.2 m | 881.5 m | 906.4 m | 925.0 m | 962.9 m | SEC (XBRL)· 19 Feb 2026verified |
Cash flow · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Capex | 485.0 m | 397.0 m | 444.0 m | 345.0 m | 317.0 m | 269.0 m | SEC (XBRL)· 19 Feb 2026verified |
| Share repurchases | 343.0 m | 1.6 bn | 187.0 m | 662.0 m | 411.0 m | 0 | SEC (XBRL)· 19 Feb 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 45.8% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
06 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Price and reporting are in different currencies; market indicators are unavailable.
Key indicators
Coverage and freshness
Score by group
46% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 18.98 – 37.42 EUR.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (EUR per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDA31.95 – 37.42 (Mid 35.76)10 companies used · median multiple 15.2x · quartiles 13.7x – 15.8xBDX, BSX, MDT, MMM, MSA, RMD, STE, SYK, XRAY, ZBH
- Peers: P/E18.98 – 31.49 (Mid 24.55)16 companies used · median multiple 26.4x · quartiles 20.4x – 33.9xBSX, CNMD, DXCM, EW, GEHC, GMED, ISRG, MDT, MMM, MSA, NVST, RMD, STE, SYK, WST, ZBH
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 45.8% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 6.8% | 48 (vs peers) | 23% |
| Net margin · Quality | 5.0% | 53 (vs peers) | 14% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 0.0% | 0 (on a fixed band) | 18% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | 1.6x | 53 (vs peers) | 23% |
| Interest coverage · Balance sheet | 4.1x | 40 (on a fixed band) | 14% |
| Current ratio · Balance sheet | 1.3x | 44 (on a fixed band) | 9% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet47/100 · 3/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality50/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
KONINKLIJKE PHILIPS NV (PHG). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 17.8 bn EUR in 2025; YoY growth -1.0%; net margin 5.0%; ROE 7.8%; net debt/EBITDA 1.6x.
The estimated value range is 25.47–34.46 EUR per share (median of 2 methods, agreement: same basis (multiples on one peer group, not independent confirmations)); assumptions are illustrative. The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 45.8% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Revenue CAGR 3Y: 0.0%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Instruments, medical and optical goods (SIC 384x) · same industry group (3-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ISRGIntuitive Surgical, Inc. | 162.4 bn | 56.7 | 18.0% | 25.5% | +20.5% | −18% / +51% |
| MDTMedtronic plc | 134.1 bn | 25.8 | 10.7% | 13.9% | +8.4% | −0% / +32% |
| SYKStryker Corp | 127.6 bn | 35.7 | 16.0% | 13.8% | +11.2% | −10% / +13% |
| MMM3m Company | 97.0 bn | 28.0 | 80.8% | 14.0% | +1.5% | +9% / +127% |
| BSXBoston Scientific Corporation | 64.7 bn | 18.9 | 14.3% | 16.6% | +19.9% | −56% / −20% |
| BDXBecton, Dickinson And Company | 58.2 bn | 64.5 | 3.8% | 4.0% | +8.2% | +40% / +15% |
| EWEdwards Lifesciences Corporation | 58.0 bn | 57.1 | 9.7% | 15.3% | +11.5% | +16% / +49% |
| GEHCGe Healthcare Technologies Inc. | 37.9 bn | 17.7 | 19.9% | 10.0% | +4.8% | +5% / +22% |
| RMDResMed Inc. | 33.7 bn | 21.8 | 26.4% | 27.8% | +9.9% | −6% / +52% |
| DXCMDexcom, Inc. | 31.5 bn | 33.3 | 37.7% | 19.4% | +15.6% | +33% / −27% |
| WSTWest Pharmaceutical Services, Inc. | 27.3 bn | 44.1 | 21.2% | 18.8% | +6.3% | +42% / +12% |
| STESTERIS plc | 24.7 bn | 29.8 | 11.6% | 13.4% | +8.7% | −5% / +26% |
| ZBHZimmer Biomet Holdings, Inc. | 20.2 bn | 27.0 | 6.0% | 9.0% | +7.2% | +10% / −8% |
| GMEDGlobus Medical, Inc. | 9.5 bn | 17.5 | 12.1% | 17.8% | +16.7% | −22% / +58% |
| MSAMsa Safety Inc | 6.6 bn | 21.9 | 22.1% | 15.0% | +3.7% | +5% / −2% |
| NVSTEnvista Holdings Corporation | 4.0 bn | 6.5 | 20.5% | 22.0% | +8.3% | +20% / +11% |
| IRTCiRhythm Holdings, Inc. | 3.0 bn | — | -25.8% | -4.5% | +26.2% | −52% / +6% |
| XRAYDENTSPLY SIRONA Inc. | 1.9 bn | — | -8.5% | -3.4% | −3.0% | −17% / −70% |
| NVCRNovoCure Limited | 1.6 bn | — | -35.2% | -16.8% | +8.3% | +4% / +8% |
| CNMDConmed Corporation | 1.5 bn | 20.9 | 7.1% | 5.4% | +5.2% | +19% / −52% |
| TNDMTandem Diabetes Care, Inc. | 1.2 bn | — | -36.7% | -4.6% | +7.9% | −20% / −16% |
| ATECAlphatec Holdings, Inc. | 1.2 bn | — | -1,888.0% | -10.3% | +25.0% | −67% / −37% |
| ZJYLJin Medical International Ltd. | 526.0 m | 336.0 | 4.1% | 5.8% | −12.0% | −33% / −86% |
| CLPTClearPoint Neuro, Inc. | 275.7 m | — | -167.5% | -79.4% | +17.8% | −41% / +49% |
| TMCITreace Medical Concepts, Inc. | 262.1 m | — | -72.0% | -29.0% | +1.6% | +35% / −54% |
1- and 3-year price returns: for PHG from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 19 Feb 2026; since then the company filed 6-K (03 Nov 2026), 6-K (28 Jul 2026), 6-K (02 Jun 2026), 6-K (08 May 2026), 6-K (06 May 2026), 6-K (30 Mar 2026).
In brief
Philips is a global medical technology group that designs imaging and therapy systems, monitoring solutions and personal health products. The company focuses its strategy on AI-enabled innovation, on rebuilding trust after the Respironics product safety issues, and on profitable growth for 2026-2028. For X-ray apparatus, the relevant segment is Diagnosis & Treatment, where imaging and image guided therapy form a major part of sales.
SWOT
Strengths
- A broad imaging and therapy portfolio, with leading positions in several categories and a large global installed base 1.
- Demonstrated innovation capacity through AI-enabled products and launches that drew customer attention in 2025 1.
- Broad partnerships with governments and health systems, including a nationwide coverage program in Indonesia 1.
Weaknesses
- Patient safety and quality issues linked to Respironics products that remain subject to regulatory requirements 1.
- Reliance on sales concentrated in the second half of the year in the Diagnosis & Treatment segment, which makes revenue harder to predict within the year 1.
- The need to improve performance in the Precision Diagnosis business, where the company identified quality and operational gaps 1.
Opportunities
Threats
- Tariff pressures that could raise costs and delay deliveries if trade measures tighten 1.
- Strong competition from global medical equipment makers that could reduce market share in some categories 1.
- Strict patient safety regulation and possible new warnings from authorities could restrict access in certain markets 1.
Risks
- Patient safety and product qualityhigh
The FDA warning letter of September 2025 and the consent decree requirements for Respironics could affect sales and the company's reputation 1.
- Trade tariffsmedium
Tariff measures could raise production costs and pressure margins if they cannot be offset through productivity gains 1.
- Seasonality of saleslow
Sales concentrated in the second half of the year make quarterly results harder to compare and could surprise investors 1.
- AI-related risksmedium
Using AI in healthcare brings regulatory and liability risks that the company describes in its risk factors section 1.
- Supply chainmedium
Supply chain resilience remains a goal, and delays or delivery variability could affect sales in the imaging segments 1.
Investment thesis
What would need to be true (bull case)
- A leading imaging and image guided therapy portfolio could support growth if demand for minimally invasive procedures continues 1.
- AI innovation and new scanning systems could raise the value of each sale and strengthen long-term customer relationships 1.
- If improved margins and cash generation are sustained, the company could have room for investment and stable dividends 1.
What would break the thesis
- The Respironics safety issues and the FDA warning letter could continue to weigh on the company's reputation and sales 1.
- Tariffs and supply costs could offset productivity gains if trade pressures increase 1.
- Intense competition from global manufacturers could limit pricing power and reduce market share in some categories 1.
What to watch
- Performance of the Precision Diagnosis business and operational qualityQ1 2027
- Results of the 2026-2028 plan and comparable sales growth2027
- Impact of tariffs on margins and the supply chainnext 10-K
- Status of FDA requirements and the Respironics consent decree2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 19 Feb 2026; since then the company filed 6-K (03 Nov 2026), 6-K (28 Jul 2026), 6-K (02 Jun 2026), 6-K (08 May 2026), 6-K (06 May 2026), 6-K (30 Mar 2026).
The business
Koninklijke Philips N.V. (Royal Philips) is the parent company of the Philips Group and coordinates three segments: Diagnosis & Treatment, Connected Care and Personal Health, plus a segment Other that includes Innovation & Design, IP royalties and central costs 1. Each segment is organized into businesses, which are made up of business units accountable for value creation. The operating model puts business units in the lead, supported by lean functions and regions.
Diagnosis & Treatment includes the Precision Diagnosis business, covering MRI, ultrasound, CT and diagnostic X-ray, and the Image Guided Therapy business, offering integrated interventional systems and specialty devices 1. Revenue comes from products, leasing, service fees and software, and many contracts include per-procedure or per-study fees. Sales in this segment are generally higher in the second half of the year because of customer spending patterns 1.
The company describes its strategy on three pillars: focused growth, scalable patient- and people-centric innovation, and reliable execution supported by its culture of impact with care 1. In 2025 management reported improved order intake and comparable sales growth, along with expanding gross and Adjusted EBITA margins, presented as results of the three-year plan 1.
Segments
Diagnosis & Treatment
This is the main segment for X-ray apparatus and imaging systems. Precision Diagnosis represented 59% of segment sales in 2025, while Image Guided Therapy represented 41% 1. Diagnostic X-ray is a business unit within Precision Diagnosis, alongside MRI, ultrasound and CT.
Connected Care
The segment includes patient monitoring in hospitals and ambulatory care, enterprise informatics (PACS and interoperability) and sleep and respiratory care. The company relies on a leading position in monitoring and a strong share in sleep therapy devices 1. This segment is less directly tied to X-ray apparatus but influences demand for imaging systems through informatics integration.
Personal Health
Personal Health brings together personal care, oral healthcare and mother and child care. The company ranks among the top players in its categories, for example in grooming and infant feeding 1. This segment has no direct link to X-ray apparatus.
Market context
The medical imaging market is contested by large manufacturers offering MRI, CT, ultrasound and X-ray systems. The company reports leading or top-three positions in several categories, but its share varies by product and region 1. Demand depends on hospital budgets, equipment replacement cycles and reimbursement rules, which the company factors into its growth plan 1.
Demand for imaging solutions that include AI is growing, and companies able to demonstrate clinical and economic benefits could gain market share 1. Tariff pressures and patient safety regulation, including the FDA warning letter issued in 2025, could influence costs and delivery timing 1.
Trends
- AI integration in imaging systemstailwind
The company is introducing imaging solutions where AI helps shorten scan times and improve image clarity, such as the SmartSpeed and Verida technologies 1. If these products are adopted widely, they could support sales growth in the Diagnosis & Treatment segment.
- Tariff pressuresheadwind
Tariff measures have pushed the company to reorganize its supply chain and cut costs, which helped improve margins in 2025 1. If tariffs tighten further, production costs could rise again.
- Recovery after the Respironics issuesmixed
The company continues to operate under consent decree requirements for Respironics in the US and received an FDA warning letter in September 2025 for three sites 1. Rebuilding trust could affect demand for respiratory care products and the reputation of the wider group.
- Innovation in image guided therapytailwind
Growth in the Image Guided Therapy business is supported by new interventional systems and the SpectraWAVE acquisition, which expands the portfolio in coronary intervention 1. If demand for minimally invasive procedures keeps rising, this business could contribute more to sales.
Competitive position
The company competes in imaging, therapy and monitoring with other global medical equipment makers. Internal estimates and market research point to top positions in the categories where Philips is active, but rankings differ by segment 1. The company says innovation is its core differentiator in an increasingly competitive environment 1.
Competitive pressure is strongest in imaging products where customers compare performance, lifecycle cost and software integration. The company responds with integrated hardware-software solutions and partnerships, for example with Edwards Lifesciences for real-time guidance in heart valve repair 1.
- GE HealthCareGEHC
Global competitor in medical imaging, including MRI, CT, ultrasound and X-ray, active in the same diagnostic markets.
- Siemens Healthineers
Major European competitor in diagnostic imaging and interventional therapy, with a strong presence in large hospitals.
- Canon Medical Systems
Japanese imaging equipment maker competing in CT, ultrasound and radiography.
- Fujifilm Healthcare
Japanese competitor active in radiography, imaging and medical informatics systems.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Philips в III квартале снизила чистую прибыль почти в 7 раз из-за мировой сделкиInterfax Russia (RU) · 03 Nov 2026 · RU
- Toate Electronicele la Carrefour care de BLACK FRIDAY 2026 au Reduceri Mari, Produse Arctic, Beko, Hama, Philips, Tellur, Braun în Ofertă - iDevice.roSurge — Google News · 30 Oct 2026 · RO
- București: Conferință pentru IT-iști, cu specialiști de la Philips, Databricks, Amazon și alte companii de tehnologieStartupCafe.ro · 13 Oct 2026 · RO
- Philips’ motion-tracking smart toothbrush uses AI to make you a better brusherThe Verge · 28 Sept 2026 · EN
- Un angajat Philips România a dezinstalat WhatsApp de pe un dispozitiv, după ce a auzit că venea Consiliul Concurenței în inspecție- acuză autoritateaHotNews.ro · 10 Sept 2026 · RO
- Consiliul Concurenței a sancționat Philips România cu un milion de euroJuridice.ro · 09 Sept 2026 · RO
- Philips România, amendată cu aproape un milion de euro de Consiliul Concurenței. Autoritatea a făcut inspecții la companie și la 10 distribuitoriEconomedia · 09 Sept 2026 · RO
- Amendă de 1 milion de euro pentru Philips România. Ce a făcut un angajat în timpul inspecției Consiliului ConcurenţeiAdevărul · 09 Sept 2026 · RO
- ULTIMA ORĂ Philips, amendă în România de la Consiliul Concurenței. Este reclamat gestul unui angajat în plin controlProfit.ro · 09 Sept 2026 · RO
- ULTIMA ORĂ Philips, amendă în România de la Consiliul ConcurențeiProfit.ro · 09 Sept 2026 · RO
- Philips România, amendată cu 1 milion de euro de Consiliul Concurenței / Un angajat a șters aplicația WhatsApp de pe telefon, în timpul unui control / S-a suspectat ascunderea unor posibile probeG4Media · 09 Sept 2026 · RO
- Un angajat Philips România a dezinstalat WhatsApp de pe un dispozitiv, după ce a auzit că venea Consiliul Concurenței în control (autoritate)StartupCafe.ro · 09 Sept 2026 · RO
- Philips Hue adds Nanoleaf’s light panels to its ecosystem with a $40 moduleThe Verge · 03 Sept 2026 · EN
- Philips Hue adds more affordable options for syncing smart lights with your TVThe Verge · 03 Sept 2026 · EN
- Un grup de studenți ai Politehnicii din București au participat la un stagiu de practică în cadrul Philips RomâniaStartupCafe.ro · 02 Sept 2026 · RO
- US convicts ex-Philips engineer for exposing X-ray secrets to competitorThe Register · 25 Aug 2026 · EN
- Philips, vizată într-o investigație a Concurenței privind dispozitivele medicale de monitorizare a paciențilorCursDeGuvernare.ro · 19 Aug 2026 · RO
- Consiliul Concurenţei investighează Philips România şi 10 distribuitori pentru posibila manipulare a achiziţiilor de echipamente medicaleEconomedia · 19 Aug 2026 · RO
- Consiliul Concurenţei a efectuat inspecţii inopinate la sediul Philips România şi la sediile a 10 distribuitori, într-o investigaţie ce vizează o posibilă înţelegere anticoncurenţială pe piaţa echipamentelor pentru spitale şi cliniciZiarul Financiar · 19 Aug 2026 · RO
- Consiliul Concurenţei a făcut inspecţii inopinate la sediul Philips România şi la sediile a 10 distribuitori, într-o investigaţie ce vizează o posibilă înţelegere anticoncurenţială pe piaţa echipamentelor pentru spitale şi cliniciZiarul Financiar · 19 Aug 2026 · RO
SEC filings
- Current report (foreign issuer)03 Nov 2026
- Current report (foreign issuer)28 Jul 2026
- Current report (foreign issuer)02 Jun 2026
- Current report (foreign issuer)08 May 2026
- Current report (foreign issuer)06 May 2026
- Current report (foreign issuer)30 Mar 2026
- Current report (foreign issuer)30 Mar 2026
- Annual report (foreign issuer)19 Feb 2026
- Current report (foreign issuer)19 Feb 2026
- Current report (foreign issuer)10 Feb 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / Koninklijke Philips N.V. · 19 Feb 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.